Results 151 to 160 of about 7,486 (163)

Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis [PDF]

Journal of Neurology
Background: Anti-CD20 monoclonal antibodies are now a common first-line treatment for multiple sclerosis (MS). Rituximab, ocrelizumab, and ofatumumab have all been associated with a dose-dependent risk of hypogammaglobulinaemia, but its relevance in ...
Emma C Tallantyre, Neil Robertson, Stephen Jolles   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis

Med, 2023
Katrin Pape, Frauke Zipp, Stefan Bittner
exaly  

Top bar navigation

Frontiers in Neurology, 2021
Angel Perez-Sempere, Antonio Palazón Bru   +1 more
exaly  

A possible case of serum sickness after ocrelizumab infusion

Multiple Sclerosis Journal, 2021
James M Stankiewicz, Vanessa F Moreira Ferreira, James Stankiewicz   +2 more
exaly  

Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database

Multiple Sclerosis Journal, 2021
Olaf Stüve, Amber Salter, Natalia Gonzalez Caldito   +2 more
exaly  

Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study

Journal of Neurology, 2022
Carlos Quintanilla-Bordás, Bonaventura Casanova, Laura Navarro   +2 more
exaly  

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)

Neurotherapeutics, 2023
Francesco Patti, Clara Grazia Chisari, Maura Danni   +2 more
exaly  

Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells

Multiple Sclerosis and Related Disorders, 2022
Paola Valentino, Gianmarco Abbadessa, Giuseppina Miele   +2 more
exaly  

Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma

Annals of Oncology, 2010
Roberto Foà, John F Seymour, M Crump
exaly  

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis

Neurotherapeutics, 2017
Bruce A C Cree, Stephen L. Hauser, Jeffrey M Gelfand   +2 more
exaly